PTGX

Over the past six months, Protagonist Therapeutics experienced several significant stock events. The FDA approved ICOTYDE™ in March 2026 for moderate-to-severe plaque psoriasis, followed by the FDA approval of MIMRYLO™ (rusfertide) on August 28, 2026, for polycythemia vera, which led to a 2.37% stock increase on that day. The company announced a $300 million share repurchase program on October 2, 2026. There were reports of insider selling, including the CFO and CEO selling shares after exercising options or as part of preset plans. Protagonist Therapeutics participated in two investment bank conferences in September 2026 and granted inducement awards in August and July 2026. While Wall Street Zen downgraded the stock to a 'buy' rating on October 10, 2026, other analysts from firms like Goldman Sachs, Truist Financial, HC Wainwright, and Wolfe Research issued 'buy' or 'outperform' ratings and increased price targets. The company reported quarterly EPS of $2.29, exceeding estimates, and revenue of $213.47 million, significantly up year-over-year. Overall, the PTGX stock increased by 34.17% over the past six months.